Aptevo Therapeutics Inc logo

Aptevo Therapeutics Inc

$ 2.14 -0.06 (-2.73%) 11:08 PM EST
P/E:
1.70
P/B:
0.69
Market Cap:
$ 10.90M
Enterprise V:
$ -1.11M
Volume:
73.50K
Avg Vol (2M):
1.16M
Also Trade In:
Volume:
73.50K
Market Cap $:
10.90M
PE Ratio:
1.70
Avg Vol (2-Month):
1.16M
Enterprise Value $:
-1.11M
PB Ratio:
0.69

Business Description

Description
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Name Current Vs Industry Vs History
Cash-To-Debt 2.18
Equity-to-Asset 0.5
Debt-to-Equity 0.64
Debt-to-EBITDA -0.42
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -7.05
Distress
Grey
Safe
Beneish M-Score -4.85
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 21.55
9-Day RSI 34.49
14-Day RSI 39.24
6-1 Month Momentum % -42.61
12-1 Month Momentum % -59.82

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.16
Quick Ratio 3.16
Cash Ratio 2.84

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -44.3